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Abstract
Disorders of the cardiac rhythm are quite prevalent in clinical practice. Though the variability 
in drug response between individuals has been extensively studied, this information has not 
been widely used in clinical practice. Rapid advances in the field of pharmacogenomics have 
provided us with crucial insights on inter-individual genetic variability and its impact on drug 
metabolism and action. Technologies for faster and cheaper genetic testing and even personal 
genome sequencing would enable  clinicians  to  optimize  prescription  based on the genetic 
makeup of the individual,  which would open up new avenues in the area of personalized 
medicine.  We  have  systematically  looked  at  literature  evidence  on  pharmacogenomics 
markers for anti-arrhythmic agents from the OpenPGx consortium collection and reason the 
applicability of genetics in the management of arrhythmia. We also discuss potential issues 
that need to be resolved before personalized pharmacogenomics becomes a reality in regular 
clinical  practice.                                           
Keywords: Arrhythmia, Pharmacogenomics, Personal genome, Genetic testing, Adverse drug 
reactions
Arrhythmias or disorders of the cardiac rhythm are not uncommon in clinical settings and one 
of the major causes of mortality and morbidity. Atrial Fibrillation is supposed to be rare in 
young healthy individuals unless without underlying cardiac pathology [1], while prevalent in 
the elderly and affects roughly around 2-5 Million individuals in the United States alone [2]. 
Ventricular fibrillation has a smaller incidence of close to 0.4 million [3]. Ventricular tachy-
arrhythmias contribute significantly to the morbidity and mortality in patients with underlying 
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coronary artery disease. It has been estimated that close to a half of deaths due to coronary 
artery disease is caused by ventricular arrhythmias [4]. Apart from the genetic and underlying 
cardiac disease as causes of cardiac rhythm abnormalities,  a number of therapeutic agents, 
including drugs not directly used in the therapy of cardiac rhythm abnormalities have now 
been implicated to cause significant prolongation of QT interval and a form of ventricular 
arrhythmia,  torsades de pointes, which is potentially  fatal  [5]. Recent reports also point to 
cardiac arrhythmias as one of the top causes for drug withdrawal and failure of clinical trials  
[6].
No major study on the incidence of arrhythmias or adverse drug reactions to anti-arrhythmic 
drugs throughout India has been performed. The lack of adequate epidemiological data in this 
important  area  has  been  highlighted  in  recent  publications  [4].  According  to  a  report  of 
arrhythmia care in India, published in 2002, the prevalence of patients with arrhythmias in the 
country  is  around  2  million  [7].  Studies  have  also  pointed  to  the  high  prevalence  of 
asymptomatic arrhythmias in elderly patients [8]. According to the reports from the National 
pharmacovigilance  programme,  several  cases  of  adverse  drug  reactions  to  anti-arrhythmic 
agents have been reported from people across India. Verapamil and Amiodarone have been 
reported to cause Steven Johnsons syndrome. Atenolol has been similarly reported to have 
adverse drug events like fatigue, cough and edema in a study conducted in South India [9]. 
Similar studies have shown Atenolol to be associated with around 4-5% of total adverse drug 
reactions  reported.                                            
Individuals vary widely in their response to therapeutic agents, and a large component of this 
variability  is  modulated  through  the  genetic  makeup  of  the  individual.  Apart  from  the 
variability in response, genetic variations are also now known to contribute significantly to 
Adverse  Drug  Reactions  (ADRs).  One  of  the  earliest  contributions  to  understanding  of 
genomics  of external  agents  have stemmed from the observations  of the British physician 
Garrod, who proposed that defects in enzymatic pathways in unusual diseases of metabolism 
could  produce  unusual  sensitivity  to  chemical  agents.  Molecular  genetic  dissection  of 
congenital conditions in humans has contributed immensely to the overall understanding of the 
genetics of heart rhythm.  The field has now grown by leaps and bounds with the advent of 
modern tools and techniques, which enables dissecting genetic phenomena at single base-pair 
resolution.  The  advent  of  genomics  technologies  has  paved  the  way  to  deciphering  the 
molecular genetic mechanisms of variability in response to therapeutic agents. This variability 
could  be  caused  by  genetic  variations,  which  modulate  the  pharmacokinetics  or 
pharmacodynamics  of  the  drug.  This  could  involve  variations  in  genes  involved  in  drug 
transport/metabolism  right  up  to  variations  in  drug-targets  and  off-targets.  The  field  of 
understanding genetic variability in the response to drugs has now emerged into a full-fledged 
branch of biology -  pharmacogenomics  with the potential  to significantly  improve disease 
management. The field has also offered novel clues towards understanding mechanisms and 
pathways,  which  involves  therapeutic  agents.                                
The last couple of decades have seen enormous improvements in the management of cardiac 
arrhythmias. Due to limited benefits and safety related concerns, very few drugs have been 
successful and have been commonly used in the treatment of arrhythmias. The field has also 
seen the emergence of newer classes of drugs which function by normalizing the channel 
activity  rather  than  blocking  them.  According  to  the  popular  Singh  Vaughan  Williams 
classification schema, drugs are placed based on the mechanism of action. The classification 
scheme has improved over time, presently including the miscellaneous class, which includes 
drugs which could not fit any of the previous classes. Recent years have seen a number of 
publications detailing the pharmacogenomics of anti-arrhythmic drugs [10-13]. Though many 
classes of anti-arrhythmic agents are not particularly used anymore currently in regular clinical 
practice  except  in  special  settings,  the  wealth  of  information  on  pharmacogenomics 
encompasses the commonly used classes of drugs as well. The Drugs and the genes involved 
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in the pharmacogenomics of anti-arrhythmics and the respective references are summarized in 
Table 1 [14-77].
Table 1. Summary of drugs, genes involved in the pharmacogenomics of anti-arrhythmic 
drugs.
Realizing  the  dream  of  personalized  medicine  is  not  without  challenges  and  focused 
intervention. The major challenge in understanding the intricacies of genomic variations and 
deciphering the potential effects on pharmacokinetics and pharmacodynamics is the lack of 
comprehensive models of drug metabolism and action for many drugs. Understanding and 
charting drug pathways is the first step towards this dream. A systems level understanding of 
the drug pathways would enable us to overlay genomic variations and offer smart guesses on 
drugs that could be involved. The drug pathways for many drugs are complicated, involving 
multiple  and sometimes redundant mechanisms for drug transport,  metabolism and targets. 
Deciphering the pathways is the first step towards understanding how genetic variation could 
potentially  contribute  to  the  changes  in  functionality  of  critical  components  of  the  drug 
pathway. In addition, it also provides crucial insights into the molecular mechanisms of drug-
drug  and  drug-environment  interactions  and  how  genetic  variations  could  modulate  this 
phenomenon. A comprehensive outline of anti-arrhythmic drugs and their drug pathways are 
summarized in Figure 1. 
The  major  area  that  would  require  focused  attention  in  the  immediate  future  is  towards 
standardized efforts to collate pharmacogenomics data and evidence to enable meta-analysis, 
while at the same time be able to keep pace with the latest avalanche of evidence brought to 
light  by  high  throughput  genomics  studies  including  Genome-wide  associations  studies 
(GWAS).  Community  led  approaches  like  PharmGKB  (www.pharmgkb.org)  and  crowd-
sourcing approaches like OpenPGx (www.openpgx.org) are the possible way forward, and both 
approaches should be organized complementary to each other. Apart from the data, the second 
focus area is computational tools and resources that can handle the high-throughput datasets. 
The availability  of  genome-wide scans  as  direct-to-consumer services  has  also provided an 
immense opportunity and challenge at the same time. With adequate computational tools and 
resources for interpretation of the data, this has the potential to lower the cost, while at the same 
time, widen the general acceptability of genetic testing. No healthcare intervention system is 
complete  without  adequate  education  and  empowerment  of  the  medical  and  paramedical 
professionals and the patients. For the success of widespread acceptability and application of 
pharmacogenomics  testing  for  cardiac  arrhythmias,  appropriate  focus  and  emphasis  on 
awareness  and  healthcare  education  is  essential.                                
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These efforts should be complemented and supplemented by both systematic ways of collecting 
data  and  being  able  to  analyze  it  to  unravel  emerging  phenomena.  This  would  necessitate 
creation of effective systems for systematic collection and sharing of clinical data, treatment 
protocols and outcome measures. This includes setting up of registries, which follow standard 
protocols, metadata and modes of data exchange. This also requires setting up collaborative and 
shared  data  resources  and  analytical  approaches.  In  summary,  seamless  exchange  of  ideas, 
resources and knowhow between research laboratories and clinicians is essential to realize the 
dream of making pharmacogenomics based personalized medicine a reality.
Figure 1: Overview of the drug pathways for anti-arrhythmic drugs. The coloured drugs and edges represent 
drugs while the metabolizing enzymes are marked as solid circles. The transporters and targets are represented as  
solid  triangles  and  rhomboids  respectively.                                 
Modeling a disease process or pathway is the next critical step in understanding the molecular  
mechanisms and the genetic architecture of disease processes. Animal models such as rodents 
and mammals have been used successfully for modeling cardiac arrhythmias. Recently advances 
include  the  application  of  newer  model  systems  for  understanding  pharmacogenomics 
principles. Model organisms like zebrafish, which are easy to maintain and study, have been 
shown to be useful in modeling pharmacological principles and potential mode of action of 
many  therapeutic  agents.                                              
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